Table 3.
Patients with events according to different genotypes in the exons 12, 21, and 26 of ABCB1
| Event | Exon 12
|
Exon 21a
|
Exon 26
|
|||
|---|---|---|---|---|---|---|
| CC(n = 54) | CT/TT(n = 93) | GG(n = 54) | GT/TT(n = 92) | CC(n = 52) | CT/TT(n = 95) | |
| Delayed graft function | 9 (17%) | 24 (26%) | 6 (11%) | 27 (29%)e | 6 (11%) | 27 (28%)e |
| Proteinuria | 14 (26%) | 24 (26%) | 14 (26%) | 24 (26%) | 10 (21%) | 28 (29%) |
| Diabetes | 7 (13%) | 17 (18%) | 7 (13%) | 17 (18%) | 4 (8%) | 20 (21%)e |
| Rejection | 30 (56%) | 43 (46%) | 29 (54%) | 43 (47%) | 27 (52%) | 46 (48%) |
| Time of the onset of AR (days) | ||||||
| median (IQ) | 24 (10–330) | 30 (16–282) | 23 (10–330) | 30 (17–282) | 22 (10–288) | 33 (15–308) |
| Graft loss | 2 (4%) | 4 (4%) | 1 (2%) | 5 (5%) | 1 (2%) | 5 (5%) |
| Cardio/cerebrovascularb | 9 (17%) | 16 (17%) | 7 (13%) | 18 (20%) | 8 (15%) | 17 (18%) |
| CMV disease | 13 (24%) | 37 (40%) | 9 (17%) | 40 (43%)f | 11 (21%) | 39 (41%)e |
| ganciclovir-treated | 13 (24%) | 33 (35%) | 9 (17%) | 36 (39%)f | 11 (21%) | 35 (37%) |
| primary CMV infectionc | 6 (11%) | 5 (5%) | 3 (6%) | 8 (9%) | 4 (8%) | 7 (7%) |
| reactivationd | 6 (11%) | 32 (34%)f | 5 (9%) | 32 (35%)f | 6 (11%) | 32 (34%)f |
| Other infectionsb | ||||||
| urinary tract | 16 (30%) | 35 (38%) | 16 (30%) | 35 (38%) | 18 (35%) | 33 (35%) |
| viral | 5 (9%) | 10 (11%) | 7 (13%) | 8 (9%) | 6 (11%) | 9 (9%) |
| pneumonias | 7 (13%) | 9 (10%) | 5 (9%) | 11 (12%) | 6 (11%) | 10 (10%) |
| other | 7 (13%) | 27 (29%)e | 6 (11%) | 28 (30%)f | 6 (11%) | 28 (29%)e |
| Cancerb | 2 (4%) | 12 (13%) | 2 (4%) | 12 (13%) | 2 (4%) | 12 (13%) |
AR, acute rejection; IQ, interquartile range; CMV, cytomegalovirus.
a
One patient was not characterized for exon 21.
b
Some patients with more than one event.
c
Primary CMV infection was defined by the presence of viral antigenemia in recipients without evidence of previous viral exposure (negative serology) at transplantation who received a graft from a seropositive donor.
d
CMV reactivation was defined by the presence of viral antigenemia in recipients with evidence of previous viral exposure (positive serology) at transplantation.
e
P < 0.05,
f
P < 0.01 versus GG (exon 21) or CC (exon 26) genotype.